Development of bi-specific T cell engagers (BiTEs) for the treatment of acute myeloid leukemia (AML)

开发用于治疗急性髓系白血病 (AML) 的双特异性 T 细胞接合剂 (BiTE)

• 批准号: 478239
• 负责人: Hirano Naoto
• 金额: $ 74.12万
• 依托单位: University Health Network (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2023
• 资助国家: 加拿大
• 起止时间: 2023-03-01 至 2028-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=478239&lang=en
• 关键词: Acute Myelogenous Leukemia; Bispecific Engager; Hla-Class Ii; Immunotherapy; Myeloperoxidase; T Cell

AML is an aggressive cancer that is difficult to treat. The usual treatment is intensive chemotherapy. Bispecific T cell engagers (BiTEs) are a new treatment option and have been successfully used to treat lymphoid cancers. BiTEs are engineered antibodies

急性粒细胞白血病是一种侵袭性癌症，很难治疗。通常的治疗方法是强化化疗。双特异性T细胞增殖剂（BiTE）是一种新的治疗选择，已成功用于治疗淋巴癌。BiTE是工程抗体